RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

NCT ID: NCT03524430

Last Updated: 2025-10-14

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 801 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-26
• Study Completion Date: 2031-03-31

Brief Summary

The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.

Detailed Description

Study Rationale:

There is some evidence that identifying non-responders early in neoadjuvant treatment and offering alternative agents (response-guided therapy) increased pathological complete response (pCR) rates and/or survival resulting in improved care and incremental cost effectiveness.

Differentiating non-responders to chemotherapy from responders with reliable guidance tools early during therapy is crucial to the success of response-guided therapy.

The current study aims to provide validation results of RDA as a tumor response assessment tool that uses tumor core biopsies starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.

Study Objectives and Endpoints:

The primary objective of the study is to determine the 2 RDI cut-offs to have a diagnostic test optimized in terms of both negative and positive predictive values NPV and PPV (in a training set of patients i.e. phase 1 of the study) for predicting nopCR/pCR and to establish the performance characteristics for the first cut-off (test result "zone 1") in terms of NPV as primary endpoint (in a validation set i.e. phase 2).

The secondary objective is to assess the test's NPV in the different cancer subtypes and the test's PPV in Her2+ patients; also to assess and compare pCR prevalence, residual cancer burden (RCB class at surgery) and DFS (secondary endpoints) in zones 1-3 for all patients and each cancer subtype.

Patient Population:

The study aims to enroll approximately 801 patients in centers in the US, Canada, Italy, Germany, Spain and France and Poland.

The population consists of patients diagnosed with invasive breast cancer and scheduled to receive neoadjuvant chemotherapy as part of standard of care treatment. Throughout the study, patients will receive standard of care neoadjuvant chemotherapy treatments including taxanes, anthracyclines or other targeted drugs and drug combinations as prescribed based on the investigators' / clinicians' choice. Adjuvant therapies (e.g. radiotherapy, hormonal treatment … etc.) may be prescribed to patients according to standard of care and independently of the RDI score results.

RDA is presently in an experimental stage and clinicians will not receive or use the RDA results in this study.

Biopsy Collection:

• 1st core needle biopsy for RDA (2 specimens): Time Point: 35 +/- days after initiation of neoadjuvant chemotherapy;
• 2nd core needle biopsy for RDA (2 specimens): Time Point: if therapy is changed (as part of SoC), a second biopsy ~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin. If Therapy is not changed (as part of SoC), a second biopsy is taken at 55 +/- 5 days after the first initiation of neoadjuvant therapy.

Statistical Plan:

The study consists of a training set / phase 1 (80 fully evaluable patients) to determine response zone cut-offs using pCR outcomes and RDA's predictive values, and a validation set / phase 2 (454 fully evaluable patients) to validate the performance characteristics of the RDA test. The study aims to enroll 801 patients in order to achieve an accrual of 534 fully evaluable patients (phase 1 and 2) which is the number required to adequately statistically power the trial. Recruitment per subgroup of cancer subtypes will be closed when the target number of fully evaluable patients per subgroup is reached for both phase 1 and 2. Combined statistical analysis and various subgroup analyses will be performed for the primary and secondary objectives.

Duration and Follow-up:

There will be an active patient accrual until last patient is accrued (to achieve the required fully evaluable patient numbers) in addition to 60 months of patient follow-up.

Conditions

Breast Neoplasm Female

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Single Interventional Study Arm

There will be 2 biopsy collection time points with 2 core needle biopsy specimens taken at each biopsy collection time point for RDA analysis during neoadjuvant chemotherapy.

Group Type: EXPERIMENTAL

Core needle biopsy

Intervention Type: PROCEDURE

1st core needle biopsy for RDA (2 specimens): Time Point: 35 +/-4 days after initiation of chemotherapy.

If no change is made to the therapy, a second biopsy (2 specimens) will be performed at 55 +/- 5 days after therapy initiation.

If there is a change of drugs, the second biopsy (2 specimens) will be performed at ~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin.

Interventions

Core needle biopsy

1st core needle biopsy for RDA (2 specimens): Time Point: 35 +/-4 days after initiation of chemotherapy.

If no change is made to the therapy, a second biopsy (2 specimens) will be performed at 55 +/- 5 days after therapy initiation.

If there is a change of drugs, the second biopsy (2 specimens) will be performed at ~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Women aged at least 18 years;
• Patients must be able to provide informed consent and sign the informed consent form to participate in the RDA study before any study procedures starts;
• Newly diagnosed clinical stage I, II or III breast cancer with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal;
• Tumour size at least 1 cm in one dimension by clinical or radiographic exam (WHO criteria);
• Must have histological confirmation of invasive breast cancer of any subtype or grade;
• Patient is scheduled for neoadjuvant chemotherapy +/- antibodies and +/- other drugs according to Standard of Care;
• Patient willing to have 2 research core needle biopsies (for RDA) taken at 2 collection timepoints during neoadjuvant chemotherapy treatment.

Exclusion Criteria

• Patient who has had prior local (i.e. surgery or radiotherapy) or systemic (i.e. endocrine or cytotoxic) therapy for the current breast cancer;
• Participation in another interventional clinical trial with concurrent treatment with experimental drugs to treat the current breast cancer during the period of neoadjuvant therapy (from diagnosis until surgery);
• Stage IV breast cancer;
• Bilateral or multicentric breast tumour;
• Prior malignant disease except curatively treated in-situ maligancies;
• Concurrent pregnancy;
• Breast feeding woman;
• Concurrent medical, psychiatric or addictive disorders that may limit the ability to give informed consent or complete the trial;
• Reasons indicating risk of poor compliance with study procedures;
• Patient not able to consent;

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Rna Diagnostics Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Maureen Trudeau, MD

Role: PRINCIPAL_INVESTIGATOR

Sunnybrook Health Sciences Center, Toronto, Canada

Daniele Generali, MD

Role: PRINCIPAL_INVESTIGATOR

SST di Cremona Multidisciplinare di Patologia Mammaria, Italy

Foluso Ademuyiwa, MD

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine, St Louis, USA

Thierry Petit, MD

Role: PRINCIPAL_INVESTIGATOR

Institut de Cancérologie, Strasbourg, France

Joke Tio, MD

Role: PRINCIPAL_INVESTIGATOR

Munster, Germany

Eva Ciruelos, MD

Role: PRINCIPAL_INVESTIGATOR

Madrid, Spain

Tomasz Jankowski, MD

Role: PRINCIPAL_INVESTIGATOR

NZOZ Neuromed, Lublin, Poland

Locations

Siteman Cancer Center

St Louis, Missouri, United States

Site Status: RECRUITING

Sunnybrook Health Sciences Center

Toronto, , Canada

Site Status: RECRUITING

Institut de Cancerologie de Strasbourg

Strasbourg, , France

Site Status: RECRUITING

Universitätsklinikum Münster

Münster, , Germany

Site Status: RECRUITING

SST di Cremona Multidisciplinare di Patologia Mammaria, Italy

Cremona, , Italy

Site Status: RECRUITING

NZOZ Neuromed

Lublin, , Poland

Site Status: RECRUITING

Hospital U. 12 de Octubre

Madrid, , Spain

Site Status: RECRUITING

Countries

United States; Canada; France; Germany; Italy; Poland; Spain

Central Contacts

Sanaa Noubir, PhD

Role: CONTACT

snoubir@rnadiagnostics.com

1-416-333-2931

John Connolly

Role: CONTACT

jconnolly@rnadiagnostics.com

1-416-985-4361

References

Parissenti AM, Guo B, Pritzker LB, Pritzker KP, Wang X, Zhu M, Shepherd LE, Trudeau ME. Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy. Breast Cancer Res Treat. 2015 Aug;153(1):135-44. doi: 10.1007/s10549-015-3498-9. Epub 2015 Jul 25.

Reference Type: BACKGROUND

PMID: 26208483 (View on PubMed)

Narendrula R, Mispel-Beyer K, Guo B, Parissenti AM, Pritzker LB, Pritzker K, Masilamani T, Wang X, Lanner C. RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines. BMC Cancer. 2016 Feb 24;16:146. doi: 10.1186/s12885-016-2197-1.

Reference Type: BACKGROUND

PMID: 26911141 (View on PubMed)

Toomey S, Eustace AJ, Pritzker LB, Pritzker KP, Fay J, O'Grady A, Cummins R, Grogan L, Kennedy J, O'Connor D, Young L, Kay EW, O'Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT. RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Natl Cancer Inst. 2016 Jul 4;108(8):djw111. doi: 10.1093/jnci/djw111. Print 2016 Aug. No abstract available.

Reference Type: BACKGROUND

PMID: 27377904 (View on PubMed)

Pritzker K, Pritzker L, Generali D, Bottini A, Cappelletti MR, Guo B, Parissenti A, Trudeau M. RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy. J Natl Cancer Inst Monogr. 2015 May;2015(51):76-80. doi: 10.1093/jncimonographs/lgv015.

Reference Type: BACKGROUND

PMID: 26063893 (View on PubMed)

Cazzaniga ME, Ademuyiwa F, Petit T, Tio J, Generali D, Ciruelos EM, Califaretti N, Poirier B, Ardizzoia A, Hoenig A, Lex B, Mouret-Reynier MA, Giesecke D, Isambert N, Masetti R, Pitre L, Wrobel D, Augereau P, Milani M, Rask S, Solbach C, Pritzker L, Noubir S, Parissenti A, Trudeau ME. Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer. JNCI Cancer Spectr. 2024 Jan 4;8(1):pkad107. doi: 10.1093/jncics/pkad107.

Reference Type: RESULT

PMID: 38113421 (View on PubMed)

Other Identifiers

RnaDx-BRV-BC- 02 (for Germany)

Identifier Type: OTHER

Identifier Source: secondary_id

RnaDx-BRV-BC- 01

Identifier Type: -

Identifier Source: org_study_id